<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398139</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2470-1343</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>40</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>ACS omega</Title><ISOAbbreviation>ACS Omega</ISOAbbreviation></Journal><ArticleTitle>Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations.</ArticleTitle><Pagination><StartPage>41583</StartPage><EndPage>41598</EndPage><MedlinePgn>41583-41598</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsomega.4c05469</ELocationID><Abstract><AbstractText>Molnupiravir, an FDA-approved nucleoside prodrug for treating COVID-19, converts into N4-hydroxycytidine triphosphate (NHC-TP), which integrates into SARS-CoV-2 RNA by its RNA-dependent RNA polymerase (RdRp) causing lethal mutations in viral proteins. Due to the risk of RdRp-mediated drug resistance and potential off-target effects on host polymerases (e.g., human polymerase II/HPolII), it is crucial to understand NHC-TP interactions at polymerase active sites for developing new, resistance-proof treatments. In this study, we used molecular dynamics (MD) simulations to probe key interactions between NHC-TP and SARS-CoV-2 RdRp and designed novel NHC-TP analogues with greater selectivity for SARS-CoV-2 RdRp over HPolII by a virtual screening workflow. We docked NHC-TP to a modified SARS-CoV-2 RdRp-Remdesivir triphosphate structure (PDB ID: 7BV2) and generated 71 NHC-TP analogues with bulky substituents to increase the interaction with RdRP and to reduce HPolII incorporation. MD simulations assessed the stability, binding affinity, and site interactions of these analogues. The top 7 candidates, with favorable ADMET properties, likely inhibit replication via potential dual mechanisms (the replicative stalling and the induction of lethal mutations) while maintaining selectivity for SARS-CoV-2 RdRp.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7505-2938</Identifier><AffiliationInfo><Affiliation>College of Science and Mathematics, Rowan University, Glassboro, New Jersey 08028, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paradis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>College of Science and Mathematics, Rowan University, Glassboro, New Jersey 08028, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunt</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Science and Mathematics, Rowan University, Glassboro, New Jersey 08028, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0176-3873</Identifier><AffiliationInfo><Affiliation>College of Science and Mathematics, Rowan University, Glassboro, New Jersey 08028, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Omega</MedlineTA><NlmUniqueID>101691658</NlmUniqueID><ISSNLinking>2470-1343</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398139</ArticleId><ArticleId IdType="pmc">PMC11465654</ArticleId><ArticleId IdType="doi">10.1021/acsomega.4c05469</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Espi M.; Charmetant X.; Barba T.; Pelletier C.; Koppe L.; Chalencon E.; Kalbacher E.; Mathias V.; Ovize A.; Cart-Tanneur E.; et al. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study. medRxiv 2021, 2125991310.1101/2021.07.02.21259913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.02.21259913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N.; Abravanel F.; Marion O.; Couat C.; Izopet J.; Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N. Engl. J. Med. 2021, 385 (7), 661–662. 10.1056/NEJMc210886110.1056/NEJMc2108861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2108861</ArticleId><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Longlune N.; Nogier M. B.; Miedougé M.; Gabilan C.; Cartou C.; Seigneuric B.; Del Bello A.; Marion O.; Faguer S.; Izopet J.; Kamar N. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol., Dial., Transplant. 2021, 36 (9), 1704–1709. 10.1093/ndt/gfab193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab193</ArticleId><ArticleId IdType="pmc">PMC8195197</ArticleId><ArticleId IdType="pubmed">34057463</ArticleId></ArticleIdList></Reference><Reference><Citation>Werbel W. A.; Boyarsky B. J.; Ou M. T.; Massie A. B.; Tobian A. A. R.; Garonzik-Wang J. M.; Segev D. L. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann. Int. Med. 2021, 174 (9), 1330–1332. 10.7326/L21-0282.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L21-0282</ArticleId><ArticleId IdType="pmc">PMC8252023</ArticleId><ArticleId IdType="pubmed">34125572</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y.; Yin W.; Xu H. E. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem. Biophys. Res. Commun. 2021, 538, 47–53. 10.1016/j.bbrc.2020.08.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.08.116</ArticleId><ArticleId IdType="pmc">PMC7473028</ArticleId><ArticleId IdType="pubmed">32943188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien M. C.; Anderson T. K.; Jockusch S.; Tao C. J.; Li X. X.; Kumar S.; Russo J. J.; Kirchdoerfer R. N.; Ju J. Y. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J. Proteome Res. 2020, 19 (11), 4690–4697. 10.1021/acs.jproteome.0c00392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00392</ArticleId><ArticleId IdType="pmc">PMC7640960</ArticleId><ArticleId IdType="pubmed">32692185</ArticleId></ArticleIdList></Reference><Reference><Citation>Babadaei M. M. N.; Hasan A.; Vahdani Y.; Bloukh S. H.; Sharifi M.; Kachooei E.; Haghighat S.; Falahati M. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. J. Biomol. Struct. Dyn. 2021, 39, 3771.10.1080/07391102.2020.1767210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1767210</ArticleId><ArticleId IdType="pmc">PMC7256352</ArticleId><ArticleId IdType="pubmed">32397906</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfiky A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020, 248, 11747710.1016/j.lfs.2020.117477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117477</ArticleId><ArticleId IdType="pmc">PMC7089605</ArticleId><ArticleId IdType="pubmed">32119961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju J. Y.; Li X. X.; Kumar S.; Jockusch S.; Chien M. C.; Tao C. J.; Morozova I.; Kalachikov S.; Kirchdoerfer R. N.; Russo J. J. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol. Res. Perspect. 2020, 8 (6), e0067410.1002/prp2.674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.674</ArticleId><ArticleId IdType="pmc">PMC7596664</ArticleId><ArticleId IdType="pubmed">33124786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad J.; Ikram S.; Ahmad F.; Rehman I. U.; Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)—A drug repurposing study. Heliyon 2020, 6 (7), e0450210.1016/j.heliyon.2020.e04502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e04502</ArticleId><ArticleId IdType="pmc">PMC7377705</ArticleId><ArticleId IdType="pubmed">32754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokic G.; Hillen H. S.; Tegunov D.; Dienemann C.; Seitz F.; Schmitzova J.; Farnung L.; Siewert A.; Hobartner C.; Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 2021, 12 (1), 27910.1038/s41467-020-20542-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20542-0</ArticleId><ArticleId IdType="pmc">PMC7804290</ArticleId><ArticleId IdType="pubmed">33436624</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J. H.; Tomashek K. M.; Dodd L. E.; Mehta A. K.; Zingman B. S.; Kalil A. C.; Hohmann E.; Chu H. Y.; Luetkemeyer A.; Kline S.; et al. Remdesivir for the Treatment of Covid-19 - Final Report. N. Engl. J. Med. 2020, 383 (19), 1813–1826. 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson F.; Khan K. S.; Le T. K.; Paris C.; Demirbag S.; Barfuss P.; Rocchi P.; Ng W. L. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol. Cell 2020, 79 (5), 710–727. 10.1016/j.molcel.2020.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.07.027</ArticleId><ArticleId IdType="pmc">PMC7402271</ArticleId><ArticleId IdType="pubmed">32853546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S.; Hill C. S.; Sarkar S.; Tse L. V.; Woodburn B. M. D.; Schinazi R. F.; Sheahan T. P.; Baric R. S.; Heise M. T.; Swanstrom R. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J. Infect. Dis 2021, 224 (3), 415–419. 10.1093/infdis/jiab247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId><ArticleId IdType="pmc">PMC8136050</ArticleId><ArticleId IdType="pubmed">33961695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp M.; Corp D.. Efficacy
and Safety of Molnupiravir
(MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001), 2020. https://ClinicalTrials.gov/show/NCT04575584.</Citation></Reference><Reference><Citation>Sharp M.; Corp D.. Efficacy
and Safety of Molnupiravir
(MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002), 2020. https://ClinicalTrials.gov/show/NCT04575597.</Citation></Reference><Reference><Citation>Kabinger F.; Stiller C.; Schmitzoval J.; Dienemann C.; Kokic G.; Hillen H. S.; Höbartner C.; Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021, 28 (9), 740–746. 10.1038/s41594-021-00651-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C. J.; Tchesnokov E. P.; Feng J. Y.; Porter D. P.; Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020, 295 (15), 4773–4779. 10.1074/jbc.AC120.013056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC120.013056</ArticleId><ArticleId IdType="pmc">PMC7152756</ArticleId><ArticleId IdType="pubmed">32094225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C. J.; Tchesnokov E. P.; Woolner E.; Perry J. K.; Feng J. Y.; Porter D. P.; Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020, 295 (20), 6785–6797. 10.1074/jbc.RA120.013679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L.; Silva D. A.; Pardo-Avila F.; Wang D.; Huang X. Structural Model of RNA Polymerase II Elongation Complex with Complete Transcription Bubble Reveals NTP Entry Routes. PLoS Comput. Biol. 2015, 11 (7), e100435410.1371/journal.pcbi.1004354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004354</ArticleId><ArticleId IdType="pmc">PMC4489626</ArticleId><ArticleId IdType="pubmed">26134169</ArticleId></ArticleIdList></Reference><Reference><Citation>Evich M.; Spring-Connell A. M.; Germann M. W. Impact of modified ribose sugars on nucleic acid conformation and function. Heterocycl. Commun. 2017, 23 (3), 155–165. 10.1515/hc-2017-0056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hc-2017-0056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W. C.; Mao C. Y.; Luan X. D.; Shen D. D.; Shen Q. Y.; Su H. X.; Wang X. X.; Zhou F. L.; Zhao W. F.; Gao M. Q.; et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020, 368 (6498), 1499–1504. 10.1126/science.abc1560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1560</ArticleId><ArticleId IdType="pmc">PMC7199908</ArticleId><ArticleId IdType="pubmed">32358203</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y.; Yan C. L.; Fang J.; Inouye C.; Tjian R.; Ivanov I.; Nogales E. Near-atomic resolution visualization of human transcription promoter opening. Nature 2016, 533 (7603), 359–365. 10.1038/nature17970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17970</ArticleId><ArticleId IdType="pmc">PMC4940141</ArticleId><ArticleId IdType="pubmed">27193682</ArticleId></ArticleIdList></Reference><Reference><Citation>Batada N. N.; Westover K. D.; Bushnell D. A.; Levitt M.; Kornberg R. D. Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (50), 17361–17364. 10.1073/pnas.0408168101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408168101</ArticleId><ArticleId IdType="pmc">PMC536049</ArticleId><ArticleId IdType="pubmed">15574497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nudler E. RNA polymerase active center: the molecular engine of transcription. Annu. Rev. Biochem. 2009, 78, 335–361. 10.1146/annurev.biochem.76.052705.164655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.76.052705.164655</ArticleId><ArticleId IdType="pmc">PMC2929140</ArticleId><ArticleId IdType="pubmed">19489723</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestro S.Maestro; Schrodinger, LLC, 2021.</Citation></Reference><Reference><Citation>Madhavi Sastry G.; Adzhigirey M.; Day T.; Annabhimoju R.; Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput.-Aided Mol. Des. 2013, 27 (3), 221–234. 10.1007/s10822-013-9644-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-013-9644-8</ArticleId><ArticleId IdType="pubmed">23579614</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood J. R.; Calkins D.; Sullivan A. P.; Shelley J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput.-Aided Mol. Des. 2010, 24 (6), 591–604. 10.1007/s10822-010-9349-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-010-9349-1</ArticleId><ArticleId IdType="pubmed">20354892</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner R. A.; Murphy R. B.; Repasky M. P.; Frye L. L.; Greenwood J. R.; Halgren T. A.; Sanschagrin P. C.; Mainz D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein–Ligand Complexes. J. Med. Chem. 2006, 49 (21), 6177–6196. 10.1021/jm051256o.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm051256o</ArticleId><ArticleId IdType="pubmed">17034125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelley J. C.; Cholleti A.; Frye L. L.; Greenwood J. R.; Timlin M. R.; Uchimaya M. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput.-Aided Mol. Des. 2007, 21 (12), 681–691. 10.1007/s10822-007-9133-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-007-9133-z</ArticleId><ArticleId IdType="pubmed">17899391</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner R. A.; Banks J. L.; Murphy R. B.; Halgren T. A.; Klicic J. J.; Mainz D. T.; Repasky M. P.; Knoll E. H.; Shelley M.; Perry J. K.; et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47 (7), 1739–1749. 10.1021/jm0306430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0306430</ArticleId><ArticleId IdType="pubmed">15027865</ArticleId></ArticleIdList></Reference><Reference><Citation>Repasky M. P.; Murphy R. B.; Banks J. L.; Greenwood J. R.; Tubert-Brohman I.; Bhat S.; Friesner R. A. Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. J. Comput.-Aided Mol. Des. 2012, 26 (6), 787–799. 10.1007/s10822-012-9575-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10822-012-9575-9</ArticleId><ArticleId IdType="pubmed">22576241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers K. J.; Chow E.; Xu H.; Dror R. O.; Eastwood M. P.; Gregersen B. A.; Klepeis J. L.; Kolossvary I.; Moraes M. A.; Sacerdoti F. D.. et al. In Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, Proceedings of the 2006 ACM/IEEE conference on Supercomputing, Tampa, FL, 2006.</Citation></Reference><Reference><Citation>Mark P.; Nilsson L. Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K. J. Phys. Chem. A 2001, 105 (43), 9954–9960. 10.1021/jp003020w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp003020w</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder E.; Damm W.; Maple J.; Wu C.; Reboul M.; Xiang J. Y.; Wang L.; Lupyan D.; Dahlgren M. K.; Knight J. L.; et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J. Chem. Theory Comput. 2016, 12 (1), 281–296. 10.1021/acs.jctc.5b00864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00864</ArticleId><ArticleId IdType="pubmed">26584231</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivakumar D.; Williams J.; Wu Y.; Damm W.; Shelley J.; Sherman W. Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. J. Chem. Theory Comput. 2010, 6 (5), 1509–1519. 10.1021/ct900587b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct900587b</ArticleId><ArticleId IdType="pubmed">26615687</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W. L.; Maxwell D. S.; Tirado-Rives J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225–11236. 10.1021/ja9621760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9621760</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X.; Li Y.; Xia Y. L.; Ai S. M.; Liang J.; Sang P.; Ji X. L.; Liu S. Q. Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods. Int. J. Mol. Sci. 2016, 17 (2), 14410.3390/ijms17020144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17020144</ArticleId><ArticleId IdType="pmc">PMC4783878</ArticleId><ArticleId IdType="pubmed">26821017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chovancova E.; Pavelka A.; Benes P.; Strnad O.; Brezovsky J.; Kozlikova B.; Gora A.; Sustr V.; Klvana M.; Medek P.; et al. CAVER 3.0: A Tool for the Analysis of Transport Pathways in Dynamic Protein Structures. PLoS Comput. Biol. 2012, 8 (10), e100270810.1371/journal.pcbi.1002708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002708</ArticleId><ArticleId IdType="pmc">PMC3475669</ArticleId><ArticleId IdType="pubmed">23093919</ArticleId></ArticleIdList></Reference><Reference><Citation>The PyMOL Molecular Graphics System, version 1.8; Schrodinger, LLC, 2015.</Citation></Reference><Reference><Citation>Daina A.; Michielin O.; Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 4271710.1038/srep42717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42717</ArticleId><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnatt A. L.; Cramer P.; Fu J. H.; Bushnell D. A.; Kornberg R. D. Structural basis of transcription:: An RNA polymerase II elongation complex at 3.3 Å resolution. Science 2001, 292 (5523), 1876–1882. 10.1126/science.1059495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1059495</ArticleId><ArticleId IdType="pubmed">11313499</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Rucobo F. W.; Cramer P. Structural basis of transcription elongation. Biochim. Biophys. Acta, Gene Regul. Mech. 2013, 1829 (1), 9–19. 10.1016/j.bbagrm.2012.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2012.09.002</ArticleId><ArticleId IdType="pubmed">22982352</ArticleId></ArticleIdList></Reference><Reference><Citation>Unarta I. C.; Goonetilleke E. C.; Wang D.; Huang X. H. Nucleotide addition and cleavage by RNA polymerase II: Coordination of two catalytic reactions using a single active site. J. Biol. Chem. 2023, 299 (2), 8.10.1016/j.jbc.2022.102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.102844</ArticleId><ArticleId IdType="pmc">PMC9860460</ArticleId><ArticleId IdType="pubmed">36581202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B. B.; Sexton R. E.; Feig M. Kinetics of nucleotide entry into RNA polymerase active site provides mechanism for efficiency and fidelity. Biochim. Biophys. Acta, Gene Regul. Mech. 2017, 1860 (4), 482–490. 10.1016/j.bbagrm.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2017.02.008</ArticleId><ArticleId IdType="pmc">PMC5393355</ArticleId><ArticleId IdType="pubmed">28242207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen H. S.; Kokic G.; Farnung L.; Dienemann C.; Tegunov D.; Cramer P. Structure of replicating SARS-CoV-2 polymerase. Nature 2020, 584 (7819), 154–156. 10.1038/s41586-020-2368-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2368-8</ArticleId><ArticleId IdType="pubmed">32438371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.; Y L.; Huang Y.; Liu F.; Zhao Y.; Cao L.; Wang T.; Sun Q.; Ming Z.; Zhang L.; Ge J.; Zheng L.; Zhang Y.; Wang H.; Zhu Y.; Zhu C.; Hu T.; Hua T.; Zhang B.; Yang X.; Li J.; Yang H.; Liu Z.; Xu W.; Guddat L. W.; Wang Q.; Lou Z.; Rao Z. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020, 368, 779–782. 10.1126/science.abb7498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7498</ArticleId><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu B.; Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc. Natl. Acad. Sci. U.S.A. 2016, 113 (28), E4005–E4014. 10.1073/pnas.1602591113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1602591113</ArticleId><ArticleId IdType="pmc">PMC4948327</ArticleId><ArticleId IdType="pubmed">27339134</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A. A.; Darwanto A.; Theruvathu J. A.; Burdzy A.; Neidigh J. W.; Sowers L. C. Impact of Sugar Pucker on Base Pair and Mispair Stability. Biochemistry 2009, 48 (50), 11994–12004. 10.1021/bi9014133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9014133</ArticleId><ArticleId IdType="pmc">PMC2814217</ArticleId><ArticleId IdType="pubmed">19899814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignon E.; Monari A. Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates. J. Chem. Inf. Model. 2022, 62 (17), 4261–4269. 10.1021/acs.jcim.2c00802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.2c00802</ArticleId><ArticleId IdType="pubmed">35982544</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranda J.; Wieczór M.; Terrazas M.; Brun-Heath I.; Orozco M. Mechanism of reaction of RNA-dependent RNA polymerase from SARS-CoV-2. Chem. Catal. 2022, 2 (5), 1084–1099. 10.1016/j.checat.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.checat.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC9016896</ArticleId><ArticleId IdType="pubmed">35465139</ArticleId></ArticleIdList></Reference><Reference><Citation>Arba M.; Wahyudi S. T.; Brunt D. J.; Paradis N.; Wu C. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. Comput. Biol. Med. 2021, 129, 10415610.1016/j.compbiomed.2020.104156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2020.104156</ArticleId><ArticleId IdType="pmc">PMC7691827</ArticleId><ArticleId IdType="pubmed">33260103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.; Mahtarin R.; Ahmed S. S.; Akter S.; Islam M. S.; Al Mamun A.; Islam R.; Hossain M. N.; Ali M. A.; Sultana M. U. C.; et al. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2. J. Biomol. Struct. Dyn. 2020, 39, 6290–6305. 10.1080/07391102.2020.1796804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1796804</ArticleId><ArticleId IdType="pmc">PMC7441766</ArticleId><ArticleId IdType="pubmed">32720571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>